Browsing by Author Dell’Orto, Patrizia

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialCoates, Alan; Abramovitz, Mark; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; et al, Various; Gray, Kathryn P; Kammler, Roswitha; Leyland-Jones, Brian; Long, Bradley; Thurlimann, B.; Young, Brandon; School of Public Health: Public HealthCYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Breast Cancer Research and Treatment, vol.151, 2, 2015,pp 373-384
2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialCoates, Alan; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; Ditzel, Henrik; et al, various; Kammler, Roswitha; Leyland-Jones, Brian; Lyng, Maria; Pagani, Olivia; Regan, Meredith M.; Tang, Weining; Thurlimann, Beat; School of Public Health: Public HealthCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial, Journal of the National Cancer Institute, vol.104, 6, 2012,pp 441-451
2015ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerCoates, Alan; Abramovitz, Mark; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; et al, Various; Gray, Kathryn P; Kammler, Roswitha; Leyland-Jones, Brian; Long, Bradley; Thurlimann, Beat; Young, Brandon; School of Public Health: Public HealthESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer, Breast Cancer Research and Treatment, vol.154, 3, 2015,pp 543-555
2015Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsCoates, Alan; Dell’Orto, Patrizia; Doimi, Franco; et al, Various; Fleming, G. F.; Francis, P A; Kammler, Roswitha; Pagani, Olivia; Regan, Meredith; Russo, Leila; Szoke, Janos; Walley, B; School of Public Health: Public HealthPredictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials, Breast Cancer Research and Treatment, vol.154, 2, 2015,pp 275-286